Phase II trial of esorubicin in advanced pancreatic adenocarcinoma.
Blayney
D W
DW
Goldberg
D A
DA
Leong
L A
LA
Carr
B I
BI
Doroshow
J H
JH
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004317:Doxorubicin; C030851:esorubicin